Darwin AG: Stock Split in Ratio 1:3 Resolved

Munich, August 13, 2025 (pta014/13.08.2025/11:00 UTC+2)

The extraordinary general meeting of Darwin AG (ISIN DE000A3C35W0) resolved today to increase the company's registered share capital in accordance with the provisions of the German Stock Corporation Act on capital increases from company funds pursuant to §§ 207 et seq., from EUR 3,000,000.00 by EUR 9,000,000.00 to EUR 12,000,000.00 by converting an amount of EUR 9,000,000.00 from the capital reserve into share capital.

The resolution on the capital increase from company funds is based on the audited annual financial statements of the company as of December 31, 2014. These audited financial statements have been issued with an unqualified audit opinion by Treuhandgesellschaft Südbayern GmbH Wirtschaftsprüfungsgesellschaft.

The capital increase will be carried out by issuing 9,000,000 bearer shares, which will be issued to the company's shareholders in a ratio of 1:3. Thus, all existing shareholders will receive 3 new bonus shares for each share held. The new shares are entitled to dividends from January 1, 2025.

As shareholders' rights to certification of their shares are excluded pursuant to § 4 para. 4 of the Articles of Association and all shares of the company are held in collective securities accounts, shareholders do not need to take any action regarding the allocation of the bonus shares. The bonus shares will be allocated to the entitled shareholders based on their holdings of old shares on the record date by crediting their collective securities accounts. The record date will be determined by the executing bank (Baader Bank AG, Munich).

The 9,000,000 bonus shares will have the same International Securities Identification Number (ISIN DE000A3C35W0) as the old shares. They are securitized in a global certificate deposited with Clearstream Banking AG, Frankfurt am Main.

"With the stock split, we aim to increase the attractiveness of the Darwin share and make it accessible to a wider circle of shareholders," commented CIO Felix Bausch.

About Darwin AG

The 'Darwin Group' (i.e., Darwin AG including its subsidiaries and sub-subsidiaries), headquartered in Munich (Germany), is a European biotechnology company specializing in human genetics. The genetic analyses carried out in its own laboratory are used in the diagnosis, therapy, and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists, or fitness trainers, and helps to ensure the most optimal treatment or care for the patient or client by analyzing their respective genetic predisposition. In addition, Darwin invests in innovative companies in the fields of biotech, healthcare, and life sciences.

Contact:

Brienner Str. 7

80333 Munich

Tel: +49 89 / 20 500 450

investor.relations@darwin-biotech.com

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)